Search results
Results from the WOW.Com Content Network
[223] [224] In 1954, the stimulant methylphenidate (Ritalin, which was first produced in 1944) became available; it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ...
The most comprehensive meta-analysis available (19 studies with over 3.9 million participants) found "no statistically significant association between ADHD medications [including methylphenidate] and the risk of cardiovascular event among children and adolescents, young and middle-aged adults, or older adults"; [44] as do other systematic ...
The gap in ADHD treatment rates for women is also getting smaller. The number of privately insured U.S. women ages 15 to 44 who filled a prescription for a medicine to treat ADHD increased 344% ...
One in four U.S. adults suspects they may have ADHD and drugs are a first line of treatment for this condition. But what does research say about their impact on the brain and quality of life?
Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. [3] [10] Common side effects include sleepiness, constipation, and dry mouth. [10]
[51] [52] The Cochrane reviews [note 4] on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects.
At high doses, prescription amphetamines, used to treat ADHD could increase a person’s risk of psychosis. Image credit: visualspace/Getty Images. This article originally appeared on Medical News ...
A meta-analysis of the global prevalence of ADHD in adults, published in 2021, estimated a collective prevalence of persistent adult ADHD of 2.58% globally in 2020. [4] Persistent adult ADHD is defined as meeting diagnostic criteria for ADHD in adulthood with the additional requirement of a confirmed childhood diagnosis. [4]